Misfolded proteins can gum up the cell’s works by glomming together and boosting inflammation. The cell, in turn, fights back by destroying the aggregated proteins. In the case of amyotrophic lateral ...

Insmed has launched a first-in-human Phase 1 trial testing its experimental ALS gene therapy INS1202 in people with the disease.

Mutations in copper-zinc superoxide dismutase 1 (SOD1) derail folding of the protein, preventing it from playing nice with its siblings. This leads the mutant down a path to aggregation and ...

Mutations in the gene SOD1 can cause the enzyme it encodes to fold in ways that are harmful to neurons—an abnormality that's responsible for about 20% of familial amyotrophic lateral sclerosis (ALS).

Amyloid Lateral Sclerosis (ALS), otherwise known as motor neuron disease (MND) or Lou Gehrig’s disease, is a neurodegenerative disorder leading to a loss of motor neurons and death, often caused by ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...

(RTTNews) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen ...

Wild-type copper–zinc superoxide dismutase (SOD1) may cause sporadic amyotrophic lateral sclerosis (ALS) via a conformation and mechanism shared with mutant SOD1—a pathogenic factor in familial ...

LEXINGTON, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it has decided to ...

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs ...